Metric Finance
LearnFAQ
LearnFAQ

Learn / GYRE

NASDAQ: GYRE

Gyre Therapeutics (GYRE) stock, explained like you're 5

Gyre Therapeutics trades on the Nasdaq under the ticker GYRE. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 785 million dollars.

Ticker
GYRE
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 785 million dollars

Is Gyre Therapeutics a small, medium or large cap company?

No. Gyre Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 785 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Gyre Therapeutics makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves GYRE stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • (GYRE) and the Role of Price Sensitive Allocations (Stock Traders Daily)
  • Gyre Therapeutics stock falls 5.00 percent to USD 6.08 on October 16, 2026 (ad-hoc-news.de)
  • Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates (Yahoo Finance)
  • H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock (ad-hoc-news.de)
  • Trading the Move, Not the Narrative: (GYRE) Edition (Stock Traders Daily)

Follow GYRE in your daily brief

Each trading day at 5 PM ET we post what happened to Gyre Therapeutics and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow GYRE

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Gyre Therapeutics stock

What does Gyre Therapeutics do?

Gyre Therapeutics trades on the Nasdaq under the ticker GYRE. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 785 million dollars.

What is the ticker symbol for Gyre Therapeutics?

Gyre Therapeutics trades under the ticker GYRE on the Nasdaq.

What is Gyre Therapeutics's market cap?

Gyre Therapeutics is a small cap stock with a market cap of about 785 million dollars.

How does Gyre Therapeutics make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves GYRE stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow GYRE stock every day?

Add GYRE to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow GYRE daily

A free brief on Gyre Therapeutics and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare GYRE: GYRE vs NVS, GYRE vs AZN, GYRE vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed